IL307358A - Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells - Google Patents

Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells

Info

Publication number
IL307358A
IL307358A IL307358A IL30735823A IL307358A IL 307358 A IL307358 A IL 307358A IL 307358 A IL307358 A IL 307358A IL 30735823 A IL30735823 A IL 30735823A IL 307358 A IL307358 A IL 307358A
Authority
IL
Israel
Prior art keywords
cells
delta
compounds
methods
pluripotent stem
Prior art date
Application number
IL307358A
Other languages
English (en)
Hebrew (he)
Inventor
Mark Wallet
Toshinobu Nishimura
Mark Mendonca
Andriana Lebid
Brenda Salantes
Katherine Santostefano
Michael Francis Naso
Buddha Gurung
Zengrong Zhu
Barry Morse
Luis Borges
Casale Christina Del
Marilda Beqiri
Lucas Thompson
Original Assignee
Century Therapeutics Inc
Mark Wallet
Toshinobu Nishimura
Mark Mendonca
Andriana Lebid
Brenda Salantes
Katherine Santostefano
Michael Francis Naso
Buddha Gurung
Zengrong Zhu
Barry Morse
Luis Borges
Casale Christina Del
Marilda Beqiri
Lucas Thompson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Century Therapeutics Inc, Mark Wallet, Toshinobu Nishimura, Mark Mendonca, Andriana Lebid, Brenda Salantes, Katherine Santostefano, Michael Francis Naso, Buddha Gurung, Zengrong Zhu, Barry Morse, Luis Borges, Casale Christina Del, Marilda Beqiri, Lucas Thompson filed Critical Century Therapeutics Inc
Publication of IL307358A publication Critical patent/IL307358A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL307358A 2021-04-07 2022-03-31 Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells IL307358A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171646P 2021-04-07 2021-04-07
US202163279837P 2021-11-16 2021-11-16
PCT/US2022/022793 WO2022216514A1 (en) 2021-04-07 2022-03-31 Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells

Publications (1)

Publication Number Publication Date
IL307358A true IL307358A (en) 2023-11-01

Family

ID=81648414

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307358A IL307358A (en) 2021-04-07 2022-03-31 Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells

Country Status (11)

Country Link
US (2) US20220333073A1 (cg-RX-API-DMAC10.html)
EP (1) EP4320227A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024519515A (cg-RX-API-DMAC10.html)
KR (1) KR20230170703A (cg-RX-API-DMAC10.html)
AU (1) AU2022252997A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023018844A2 (cg-RX-API-DMAC10.html)
CA (1) CA3214045A1 (cg-RX-API-DMAC10.html)
IL (1) IL307358A (cg-RX-API-DMAC10.html)
MX (1) MX2023011927A (cg-RX-API-DMAC10.html)
TW (1) TW202305113A (cg-RX-API-DMAC10.html)
WO (1) WO2022216514A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
EP4289940A4 (en) * 2021-02-05 2025-02-26 National University Corporation Kobe University ?? T-CELLS FROM INDUCED PLURIPOTENT STEM CELLS AND PRODUCTION PROCESSES THEREFOR
IL314801A (en) 2022-02-22 2024-10-01 Juno Therapeutics Inc Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses
CN119630695A (zh) 2022-06-08 2025-03-14 世纪治疗股份有限公司 表达cd16变体和nkg2d的遗传工程化细胞及其用途
CN120435498A (zh) 2022-11-10 2025-08-05 世纪治疗股份有限公司 具有抗-nectin4嵌合抗原受体的基因工程化细胞及其用途
WO2024191989A1 (en) * 2023-03-14 2024-09-19 Shattuck Labs, Inc. Treatment of b cell-mediated diseases by activating cd20-targeted gamma delta t cells
US20260234216A1 (en) * 2023-03-30 2026-08-13 Yale University Universal antibody receptors, guar-t cells and therapeutic use thereof
WO2024254013A1 (en) * 2023-06-04 2024-12-12 Cytovia Therapeutics, Llc. Natural killer cells with novel il-15 knock-in and methods of use thereof
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
CN118845737A (zh) * 2024-07-08 2024-10-29 海南大学 托瑞米芬在增强γδT细胞抗肿瘤功能中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344321B1 (en) 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8574179B2 (en) 2004-09-17 2013-11-05 Stp Swiss Therapeutic Products Ag Enhanced biomechanical stimulation device
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
ES2587395T3 (es) 2008-06-04 2016-10-24 Cellular Dynamics International, Inc. Procedimientos para la producción de células IPS usando un enfoque no vírico
EP3450545B1 (en) 2008-10-24 2023-08-23 Wisconsin Alumni Research Foundation Pluripotent stem cells obtained by non-viral reprogramming
CA2753679C (en) 2009-02-27 2021-03-02 Cellular Dynamics International, Inc. Differentiation of pluripotent cells
EP4420730A3 (en) 2009-03-19 2024-11-13 The Johns Hopkins University Psma-targeting compounds and uses thereof
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
US9206394B2 (en) 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
EP2601289B1 (en) 2010-08-04 2017-07-12 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
WO2012109208A2 (en) 2011-02-08 2012-08-16 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
DE102012006356A1 (de) 2012-03-28 2013-10-02 Audi Ag Kraftfahrzeug, umfassend mehrere aktive oder passive Sicherheitsvorrichtungen
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
WO2015143029A1 (en) 2014-03-18 2015-09-24 The Johns Hopkins University Psma-based molecular-genetic reporter system
AU2015290554A1 (en) 2014-07-18 2017-03-09 Kyoto University Method for inducing T cells for cell-based immunotherapy from pluripotent stem cells
WO2017070333A1 (en) 2015-10-20 2017-04-27 Cellular Dynamics International, Inc. Multi-lineage hematopoietic precursor cell production by genetic programming
JP6976960B2 (ja) * 2015-11-27 2021-12-08 カーサリクス プロプライエタリー リミテッド 遺伝子改変された細胞およびその使用
LT3444334T (lt) 2016-04-15 2021-12-10 Kyoto University Antigenui specifinių cd8 teigiamų t ląstelių indikavimo būdas
CN118546961A (zh) 2016-08-26 2024-08-27 贝勒医学院 用于细胞治疗的组成型活性细胞因子受体
JP7215994B2 (ja) 2016-09-06 2023-01-31 ザ チルドレンズ メディカル センター コーポレーション 人工多能性幹細胞由来の免疫細胞
KR102397771B1 (ko) 2016-09-23 2022-05-13 프레드 헛친슨 켄서 리서치 센터 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도
JP7212615B2 (ja) 2016-10-05 2023-01-25 フジフィルム セルラー ダイナミクス,インコーポレイテッド 多能性幹細胞からhlaホモ接合免疫細胞への指向分化方法
EP3572502B1 (en) * 2017-01-20 2023-01-11 Kyoto University Method for producing cd8alpha +beta + cytotoxic t cells
JP7224021B2 (ja) * 2017-02-03 2023-02-17 国立大学法人神戸大学 人工多能性幹細胞の作製方法
MX2019012017A (es) 2017-04-07 2020-02-12 Juno Therapeutics Inc Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
CN110891967B (zh) 2017-04-18 2025-03-14 富士胶片细胞动力公司 抗原特异性免疫效应细胞
TW201908335A (zh) 2017-07-25 2019-03-01 美國德州系統大學評議委員會 增強之嵌合抗原受體及其用途
EP3684816B1 (en) 2017-09-22 2024-05-29 Kite Pharma, Inc. Chimeric polypeptides and uses thereof
EP3692057B9 (en) 2017-10-03 2023-10-04 Precision BioSciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
CN111556892A (zh) * 2017-12-08 2020-08-18 菲特治疗公司 使用增强的iPSC衍生的效应细胞的免疫疗法
EP3822342A4 (en) * 2018-07-13 2022-08-03 Kyoto University METHOD OF PRODUCTION OF GAMMA DELTA T-CELLS
AU2019345052B2 (en) 2018-09-19 2025-09-04 FUJIFILM Cellular Dynamics, Inc. Protein L for activation and expansion of chimeric antigen receptor-modified immune cells
EP4578507A3 (en) * 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
JP7747352B2 (ja) * 2020-12-28 2025-10-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 操作されたガンマデルタt細胞ならびにその作製方法および使用方法

Also Published As

Publication number Publication date
WO2022216514A1 (en) 2022-10-13
WO2022216514A9 (en) 2023-12-21
JP2024519515A (ja) 2024-05-15
EP4320227A1 (en) 2024-02-14
CA3214045A1 (en) 2022-10-13
MX2023011927A (es) 2023-10-23
US20250066728A1 (en) 2025-02-27
KR20230170703A (ko) 2023-12-19
TW202305113A (zh) 2023-02-01
AU2022252997A1 (en) 2023-09-28
BR112023018844A2 (pt) 2023-10-10
US20220333073A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
EP3924375A4 (en) UNIVERSAL DONOR STEM CELLS AND RELATED METHODS
IL284640A (en) Pcsk9 inhibitors and methods of use thereof
IL284661A (en) Pcsk9 inhibitors and methods of use thereof
PL3817602T3 (pl) Urządzenie do wytwarzania aerozolu i sposób jego działania
EP3368660A4 (en) METHOD FOR GENERATING T-CELLS FROM STEM CELLS AND IMMUNOTHERAPEUTIC PROCEDURES USING T-CELLS
IL269203A (en) Compositions and methods for selective elimination and replacement of hematopoietic stem cells
EP3491134A4 (en) Human induced pluripotent stem cells for highly efficient genetic manipulation
EP3430132C0 (en) GENERATION OF MIDBRRAIN-SPECIFIC ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS
EP3580332A4 (en) METHODS AND REQUIREMENTS TO GENERATE NATURAL MIMETIC IMMUNE CELLS FROM PLURIPOTENT STEM CELLS
IL285083A (en) Culture media for pluripotent stem cells
UY33959A (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.3 Y NaV1.7
IL262554A (en) Purification method for pancreatic precursor cells derived from pluripotent stem cells and amplification method therefor
EP3423056A4 (en) METHODS OF REGULATING STEM CELL PROLIFERATION / GENERATION OF INNER EAR HEARING CELLS USING GSK-3-ALPHA INHIBITORS
EP3584313A4 (en) PRESERVATION CULTURE OF INTESTINAL STEM CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS
KR102246582B9 (ko) 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법
EP3808856A4 (en) UNDIFFERENTIATED CELL DETECTION METHOD
EP3706782A4 (en) COMPOSITIONS AND METHODS OF USING MANIPULATED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELL PROCESSES
EP4463171A4 (en) Hypoimmune beta cells differentiated from pluripotent stem cells and associated uses and methods
EP3808835A4 (en) CELL CULTURE SYSTEM AND CELL CULTURE PROCESS
IL299405A (en) Methods for deriving dopaminergic neurons from pluripotent stem cells
IL290297A (en) Modified cytotoxic t cells and methods of use thereof
EP3902909A4 (en) METHODS OF REGULATION OF POTENCY OF PLURIPOTENT STEM CELLS AND APPLICATIONS THEREOF
EP3642333C0 (en) NEW PRODUCTION AND USE METHODS FOR HUMAN-INDUCED NEURAL BORDER STEM CELLS
DK3425390T3 (da) Sammensætning til fremme af differentiering og beskyttelse af neurale stamceller og fremgangsmåde til induktion af neural regenerering ved anvendelse heraf
IL283007A (en) Cell culture system and method